TRIDENT LIFELINE
|
The Current P/E Ratio of TRIDENT LIFELINE is 27.23.
| Share Price | ₹310.8 | Nov 25,2025 |
| Market Cap | ₹360.5 Cr | |
| Earnings-TTM | ₹13.2 Cr | TTM-Consolidated Results |
| Price/Earnings | 27.23x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of TRIDENT LIFELINE
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹360.5 Cr] as on Nov 25,2025
(/) Earnings [ ₹13.2 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 27.23x ]
Thus, for TRIDENT LIFELINE , the investors are currently willing to pay 27.23 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of TRIDENT LIFELINE !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of TRIDENT LIFELINE over the last five years.
Historical PE (Price/Earnings) ratio chart of TRIDENT LIFELINE
PE Ratio Performance Analysis for TRIDENT LIFELINE
- TRIDENT LIFELINE 's p/e ratio for fiscal years ending Mar2025 to Mar2022 averaged 21.32x.
- TRIDENT LIFELINE 's operated at median p/e ratio of 29.71x from fiscal years ending March 2018 to 2022.
- Looking back at the last 4 fiscal years, TRIDENT LIFELINE 's p/e ratio peaked in Mar2023 at 30.41x.
- TRIDENT LIFELINE 's p/e ratio hit its five-year low in Mar2022 of 0x.
How does TRIDENT LIFELINE 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| TRIDENT LIFELINE | 13.24 | 27.23 | 360.5 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 40.42 | 425,102.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 68.53 | 170,299.0 |
| CIPLA LTD | 5,453.86 | 22.32 | 121,735.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 59.23 | 126,753.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.03 | 103,155.0 |
| MANKIND PHARMA LTD | 1,767.06 | 52.40 | 92,592.0 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.77 | 93,328.2 |
| LUPIN LTD | 4,347.53 | 21.48 | 93,364.5 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.34 | 70,131.8 |
| ABBOTT INDIA LTD | 1,508.95 | 42.63 | 64,331.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs TRIDENT LIFELINE 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.03x |
| Max industry PE | 68.53x |
| Median industry PE | 27.23x |
| Average industry PE | 35.58x |
You may also like the below Video Courses